Gene-Edited immune cells take on tough lymphoma
NCT ID NCT00368082
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 32 times
Summary
This early-phase study tests a new cell therapy for patients with relapsed EBV-positive lymphoma. The treatment uses the patient's own immune cells, modified to resist a tumor's defense mechanism (TGFb) and trained to attack cancer cells. The main goals are to find a safe dose and check for side effects in up to 8 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Houston Methodist Hospital
Houston, Texas, 77030, United States
-
Texas Childrens Hospital
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.